STADA: Purchase of a branded product portfolio for the EU markets in Central Europe successfully concluded

STADA Arzneimittel AG  / Key word(s): Mergers & Acquisitions

31.01.2012 14:16

Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Bad Vilbel, January 31, 2012 - Today, on January 31, 2012, STADA
Arzneimittel AG successfully concluded the purchase of a branded product
portfolio including the associated sales structures for EU markets
(including Poland) in Central Europe (see ad hoc release of May 12, 2011 on
the assumption of the contract negotiations, the ad hoc update of July 22,
2011 on the signing of the contracts, the ad hoc update of January 1, 2012
on the withdrawal from the purchase of the branded product portfolio in
Central Europe as well as the ad hoc update of January 27, 2012 on the
renewed signing of the contracts for Central Europe, each published via
DGAP).

The branded product portfolio for Central Europe will be consolidated in
the STADA Group from February 1, 2012.

STADA had already previously successfully concluded the purchase of the
branded product portfolio including the associated sales structures for
numerous national markets in Eastern Europe (including Russia and Ukraine)
as well as in the Middle East (see ad hoc release of May 12, 2011 on the
assumption of contract negotiations, the ad hoc update of July 22, 2011 on
the signing of the contracts as well as the ad hoc update of December 30,
2011 on the conclusion of the purchase in Eastern Europe and the Middle
East, each published via DGAP).


Additional information: 
STADA Arzneimittel AG / Corporate Communications / Stadastraße 2-18 / D -
61118 Bad Vilbel /
Phone: +49 (0) 6101 603-113 / Fax: +49 (0) 6101 603-506 / E-mail:
communications@stada.de
Or visit us in the Internet at www.stada.com.


31.01.2012 DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de

---------------------------------------------------------------------------
 
Language:     English
Company:      STADA Arzneimittel AG
              Stadastraße 2-18
              61118 Bad Vilbel
              Germany
Phone:        +49 (0)6101 603- 113
Fax:          +49 (0)6101 603- 506
E-mail:       communications@stada.de
Internet:     www.stada.de
ISIN:         DE0007251803, DE0007251845, 
WKN:          725180, 725184, 
Indices:      MDAX
Listed:       Regulierter Markt in Düsseldorf, Frankfurt (Prime Standard);
              Freiverkehr in Berlin, Hamburg, Hannover, München, Stuttgart
 
End of Announcement                             DGAP News-Service
 
---------------------------------------------------------------------------